688336 三生国健
已收盘 12-17 15:00:01
资讯
新帖
简况
12月15日三生国健跌5.83%,交银医药创新股票A基金重仓该股
证券之星 · 12-15 15:35
12月15日三生国健跌5.83%,交银医药创新股票A基金重仓该股
三生国健(688336)披露关于收到实际控制人《解除<一致行动协议>的通知函》的提示性公告,12月12日股价上涨3.48%
证券之星 · 12-12
三生国健(688336)披露关于收到实际控制人《解除<一致行动协议>的通知函》的提示性公告,12月12日股价上涨3.48%
11月27日三生国健跌5.40%,交银医药创新股票A基金重仓该股
证券之星 · 11-27
11月27日三生国健跌5.40%,交银医药创新股票A基金重仓该股
每周股票复盘:三生国健(688336)股东拟减持不超1.00%股份
证券之星 · 11-16
每周股票复盘:三生国健(688336)股东拟减持不超1.00%股份
三生国健(688336)披露股东减持股份计划公告,11月10日股价下跌0.35%
证券之星 · 11-10
三生国健(688336)披露股东减持股份计划公告,11月10日股价下跌0.35%
三生国健(688336.SH):达佳国际拟减持不超1%股份
智通财经 · 11-09
三生国健(688336.SH):达佳国际拟减持不超1%股份
每周股票复盘:XD三生国(688336)三生国健股价异动因涨幅偏离值超30%
证券之星 · 11-09
每周股票复盘:XD三生国(688336)三生国健股价异动因涨幅偏离值超30%
三生国健(688336.SH):辉瑞在某网站上登记PD-1/VEGF双抗PF-08634404(SSGJ-707)的两项全球III期临床试验其最终付款尚存在不确定性
智通财经 · 11-03
三生国健(688336.SH):辉瑞在某网站上登记PD-1/VEGF双抗PF-08634404(SSGJ-707)的两项全球III期临床试验其最终付款尚存在不确定性
股市必读:三生国健10月31日涨停收盘,收盘价72.96元
证券之星 · 11-03
股市必读:三生国健10月31日涨停收盘,收盘价72.96元
每周股票复盘:三生国健(688336)因股价涨幅达15%登龙虎榜
证券之星 · 11-02
每周股票复盘:三生国健(688336)因股价涨幅达15%登龙虎榜
三生国健:707项目的全球权益已经授权许可给辉瑞
证券日报 · 10-31
三生国健:707项目的全球权益已经授权许可给辉瑞
10月31日三生国健(688336)龙虎榜数据:北向资金净买入1493.01万元
证券之星 · 10-31
10月31日三生国健(688336)龙虎榜数据:北向资金净买入1493.01万元
三生国健涨20.00%,开源证券三日前给出“买入”评级
证券之星 · 10-31
三生国健涨20.00%,开源证券三日前给出“买入”评级
三生制药引爆创新药行情,三生国健20CM涨停
每日经济新闻 · 10-31
三生制药引爆创新药行情,三生国健20CM涨停
异动快报:三生国健(688336)10月31日10点32分触及涨停板
证券之星 · 10-31
异动快报:三生国健(688336)10月31日10点32分触及涨停板
每周股票复盘:三生国健(688336)Q3净利同比增71.15%
证券之星 · 10-26
每周股票复盘:三生国健(688336)Q3净利同比增71.15%
三生国健(688336)2025年三季报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 10-25
三生国健(688336)2025年三季报简析:营收净利润同比双双增长,盈利能力上升
10月24日三生国健跌8.62%,泰信医疗服务混合发起式A基金重仓该股
证券之星 · 10-24
10月24日三生国健跌8.62%,泰信医疗服务混合发起式A基金重仓该股
三生国健(688336)披露2025年第三季度报告,10月23日股价上涨0.67%
证券之星 · 10-23
三生国健(688336)披露2025年第三季度报告,10月23日股价上涨0.67%
三生国健最新公告:第三季度净利润同比增长101.41%
证券之星 · 10-23
三生国健最新公告:第三季度净利润同比增长101.41%
暂无数据
公司概况
公司名称:
三生国健药业(上海)股份有限公司
所属行业:
医药制造业
上市日期:
2020-07-22
主营业务:
三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普、赛普汀、健尼哌。公司是“免疫与炎症全国重点实验室”依托单位、拥有抗体药物国家工程研究中心、国家企业技术中心、上海市抗体技术创新中心、上海抗体工程技术研究中心等国家级和上海市级高新技术平台,承担过国家重大新药创制、“863”计划、国家发改委及上海市重大项目及各部委课题百余项,多次获得上海市级和浦东新区科学技术奖。
发行价格:
28.18
{"stockData":{"symbol":"688336","market":"SH","secType":"STK","nameCN":"三生国健","latestPrice":59.65,"timestamp":1765954801000,"preClose":59.3,"halted":0,"volume":2690592,"delay":0,"changeRate":0.0059,"floatShares":617000000,"shares":617000000,"eps":1.4112,"marketStatus":"已收盘","change":0.35,"latestTime":"12-17 15:00:01","open":59.33,"high":59.8,"low":58.69,"amount":159000000,"amplitude":0.0187,"askPrice":59.65,"askSize":25,"bidPrice":59.6,"bidSize":2,"shortable":0,"etf":0,"ttmEps":1.4112,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766021400000},"marketStatusCode":5,"adr":0,"adjPreClose":59.3,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765935000000,1765942200000],[1765947600000,1765954800000]],"highLimit":65.23,"lowLimit":53.37,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":616785793,"isCdr":false,"pbRate":6.24,"roa":"--","peRate":42.268991,"roe":"6.95%","epsLYR":1.14,"committee":-0.48,"marketValue":36791000000,"turnoverRate":0.0044,"status":0,"afterMarket":{"amount":0,"volume":0,"close":59.65,"buyVolume":0,"sellVolume":0,"time":1765956837768,"indexStatus":"已收盘 12-17 15:30:00","preClose":59.3},"floatMarketCap":36791000000},"requestUrl":"/m/hq/s/688336/tweets","defaultTab":"tweets","newsList":[{"id":"2591861598","title":"12月15日三生国健跌5.83%,交银医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591861598","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591861598?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:35","pubTimestamp":1765784122,"startTime":"0","endTime":"0","summary":"证券之星消息,12月15日三生国健跌5.83%,收盘报60.7元,换手率0.85%,成交量5.24万手,成交额3.22亿元。重仓三生国健的前十大公募基金请见下表:该股最近90天内共有7家机构给出评级,买入评级4家,增持评级3家;过去90天内机构目标均价为70.27。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共19家,其中持有数量最多的公募基金为交银施罗德基金的交银医药创新股票A。该公募基金现任基金经理为楼慧源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500012975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09939","BK0239","BK1515","688336","159938","BK1574"],"gpt_icon":0},{"id":"2590727265","title":"三生国健(688336)披露关于收到实际控制人《解除<一致行动协议>的通知函》的提示性公告,12月12日股价上涨3.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590727265","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590727265?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:52","pubTimestamp":1765533153,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘,三生国健报收于64.46元,较前一交易日上涨3.48%,最新总市值为397.58亿元。同日,三生国健发布公告称,公司收到实际控制人LOU JING出具的《解除<一致行动协议>的通知函》。根据公告内容,LOU JING与TAN BO、苏冬梅、黄斌签署的《一致行动协议》自签署通知函之日起解除。LOU JING通过三生制药及其下属企业和香港达佳合计控制公司84.96%股份的表决权,可支配的表决权比例未发生变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200028638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2586217581","title":"11月27日三生国健跌5.40%,交银医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586217581","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586217581?lang=zh_cn&edition=full","pubTime":"2025-11-27 15:33","pubTimestamp":1764228808,"startTime":"0","endTime":"0","summary":"证券之星消息,11月27日三生国健跌5.40%,收盘报64.7元,换手率0.98%,成交量6.04万手,成交额4.0亿元。重仓三生国健的前十大公募基金请见下表:该股最近90天内共有7家机构给出评级,买入评级4家,增持评级3家;过去90天内机构目标均价为66.63。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共19家,其中持有数量最多的公募基金为交银施罗德基金的交银医药创新股票A。该公募基金现任基金经理为楼慧源。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700017113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09939","159938","BK1515","BK1574","688336","BK1161"],"gpt_icon":0},{"id":"2583593966","title":"每周股票复盘:三生国健(688336)股东拟减持不超1.00%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593966","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583593966?lang=zh_cn&edition=full","pubTime":"2025-11-16 01:56","pubTimestamp":1763229370,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,三生国健报收于72.37元,较上周的65.23元上涨10.95%。本周,三生国健11月14日盘中最高价报77.26元。达佳国际拟在2025年12月1日至2026年2月28日期间,通过集中竞价方式减持不超过6,167,857股,即不超过公司总股本的1.00%,减持原因为自身资金需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2582299788","title":"三生国健(688336)披露股东减持股份计划公告,11月10日股价下跌0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582299788","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582299788?lang=zh_cn&edition=full","pubTime":"2025-11-10 17:22","pubTimestamp":1762766555,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘,三生国健报收于65.0元,较前一交易日下跌0.35%,最新总市值为400.91亿元。公司近日发布公告称,截至公告披露日,达佳国际(香港)有限公司持有三生国健股份25,160,657股,占总股本的4.08%。达佳国际拟在2025年12月1日至2026年2月28日期间,通过集中竞价方式减持不超过6,167,857股,即不超过公司总股本的1.00%,减持原因为自身资金需求。本次减持计划不会导致公司控制权变更,且符合相关法律法规及承诺要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000022731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"gpt_icon":0},{"id":"2582932896","title":"三生国健(688336.SH):达佳国际拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2582932896","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582932896?lang=zh_cn&edition=full","pubTime":"2025-11-09 15:35","pubTimestamp":1762673715,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生国健(688336.SH)发布公告,根据股东自身资金需求,达佳国际拟在本次减持计划公告之日起15个交易日后的三个月内,以集中竞价方式择机减持其所持公司股份合计不超过616.79万股,即不超过公司总股本的1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688336"],"gpt_icon":0},{"id":"2582668768","title":"每周股票复盘:XD三生国(688336)三生国健股价异动因涨幅偏离值超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582668768","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582668768?lang=zh_cn&edition=full","pubTime":"2025-11-09 01:15","pubTimestamp":1762622112,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,XD三生国报收于65.23元,较上周的72.96元下跌10.59%。本周,XD三生国11月3日盘中最高价报83.0元,股价触及近一年最高点。本周关注点来自交易信息汇总:三生国健因连续3个交易日涨幅偏离值累计达30%两度登上龙虎榜。来自公司公告汇总:三生国健股票交易连续两个交易日涨幅偏离值累计超过30%,构成异常波动。公司董事、高管及控股股东在异常波动期间未买卖公司股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2580966482","title":"三生国健(688336.SH):辉瑞在某网站上登记PD-1/VEGF双抗PF-08634404(SSGJ-707)的两项全球III期临床试验其最终付款尚存在不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2580966482","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580966482?lang=zh_cn&edition=full","pubTime":"2025-11-03 18:25","pubTimestamp":1762165505,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生国健 发布股价异动公告称,公司及三生制药和沈阳三生共同授予被许可方辉瑞公司在许可区域及领域的独家开发、生产和商业化许可产品707项目的权利。《许可协议》于2025年7月24日正式生效。2025年10月30日,辉瑞在ClinicalTrials.gov网站上登记了PD-1/VEGF双抗PF-08634404的两项全球III期临床试验。鉴于《许可协议》中所约定的里程碑付款需要满足一系列特定条件,其最终付款尚存在不确定性,敬请广大投资者注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","SG9999002224.SGD","BK0239","LU1169589451.USD","IE00B19Z3B42.SGD","BK4007","BK4592","IE00BBT3K403.USD","LU0306806265.USD","LU1894683348.USD","LU1883839398.USD","LU1894683264.USD","LU0306807586.USD","LU1169590202.USD","IE00B19Z3581.USD","LU1023059063.AUD","IE000M9KFDE8.USD","BK4023","SG9999002232.USD","BK4533","LU0321505439.SGD","SG9999013999.USD","LU0058720904.USD","SG9999001176.USD","IE00BLSP4239.USD","LU0321505868.SGD","PD","BK4134","III","LU0289739699.SGD","LU0122379950.USD","LU0170899867.USD","LU0225771236.USD","LU1066051498.USD","SG9999001176.SGD","LU0225284248.USD","LU0456855351.SGD","LU0868494617.USD","LU0234572021.USD","LU0985481810.HKD","BK4550","BK4568","BK4534","BK4581","LU1057294990.SGD","LU1066053197.SGD","688336","SG9999003800.SGD","SGXZ57979304.SGD"],"gpt_icon":0},{"id":"2580428707","title":"股市必读:三生国健10月31日涨停收盘,收盘价72.96元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580428707","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580428707?lang=zh_cn&edition=full","pubTime":"2025-11-03 00:49","pubTimestamp":1762102152,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,三生国健报收于72.96元,上涨20.0%,涨停,换手率1.87%,成交量11.52万手,成交额7.99亿元。来自公司公告汇总:三生国健公布2025年半年度权益分派方案,每股派发现金红利0.033元(含税),股权登记日为2025年11月6日。交易信息汇总三生国健10月31日涨停收盘,收盘价72.96元。该股于10点30分涨停,1次打开涨停,截至收盘封单资金为285.51万元,占其流通市值0.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300000191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"gpt_icon":0},{"id":"2580781114","title":"每周股票复盘:三生国健(688336)因股价涨幅达15%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2580781114","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580781114?lang=zh_cn&edition=full","pubTime":"2025-11-02 01:35","pubTimestamp":1762018513,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,三生国健报收于72.96元,较上周的54.83元上涨33.07%。本周,三生国健10月31日盘中最高价报72.96元,股价触及近一年最高点。本周关注点来自交易信息汇总:三生国健因日收盘价格涨幅达15%登上龙虎榜。来自公司公告汇总:三生国健拟每股派发现金红利0.033元(含税),股权登记日为2025年11月6日。公司公告汇总三生国健药业(上海)股份有限公司2025年半年度权益分派实施公告,证券代码688336,公告编号2025-060。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2579493919","title":"三生国健:707项目的全球权益已经授权许可给辉瑞","url":"https://stock-news.laohu8.com/highlight/detail?id=2579493919","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579493919?lang=zh_cn&edition=full","pubTime":"2025-10-31 22:09","pubTimestamp":1761919740,"startTime":"0","endTime":"0","summary":"证券日报网讯三生国健10月31日在互动平台回答投资者提问时表示,707项目的全球权益已经授权许可给辉瑞,后期临床计划由辉瑞主导推进,公司聚焦在自身免疫性疾病领域。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-31/doc-infvvcym5384023.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-31/doc-infvvcym5384023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SG9999001176.SGD","IE00BLSP4239.USD","BK4581","IE000M9KFDE8.USD","SG9999001176.USD","LU0868494617.USD","IE00BBT3K403.USD","LU1894683264.USD","SG9999011175.SGD","SG9999002232.USD","LU1066051498.USD","BK4007","BK4585","LU0456855351.SGD","SG9999003800.SGD","LU0985481810.HKD","IE00B19Z3B42.SGD","LU0225771236.USD","BK4568","IE0002270589.USD","LU0321505439.SGD","SGXZ57979304.SGD","BK0239","BK4599","LU0321505868.SGD","SG9999013999.USD","LU1066053197.SGD","SG9999002224.SGD","LU0289739699.SGD","688336","BK4550","LU0225284248.USD","LU1057294990.SGD","BK4533","BK4534","BK4588","LU1023059063.AUD","LU0058720904.USD","LU0234572021.USD","LU0170899867.USD","IE00B19Z3581.USD","LU1894683348.USD","LU0306806265.USD","LU1883839398.USD","LU0122379950.USD","BK4592","LU0306807586.USD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2579586454","title":"10月31日三生国健(688336)龙虎榜数据:北向资金净买入1493.01万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579586454","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579586454?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:48","pubTimestamp":1761904094,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2025年10月31日公布的交易公开信息显示,三生国健因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年10月31日收盘,三生国健报收于72.96元,上涨20.0%,涨停,换手率1.87%,成交量11.52万手,成交额7.99亿元。从龙虎榜公布的当日买卖数据来看,北向资金合计净买入1493.01万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100037750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2579453117","title":"三生国健涨20.00%,开源证券三日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2579453117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579453117?lang=zh_cn&edition=full","pubTime":"2025-10-31 16:26","pubTimestamp":1761899177,"startTime":"0","endTime":"0","summary":"今日三生国健涨20.00%,收盘报72.96元。2025年10月28日,开源证券研究员余汝意,余克清,汪晋发布了对三生国健的研报《公司信息更新报告:业绩同环比增速稳健,在研项目稳步推进》,该研报对三生国健给出“买入”评级。研报中预计2025-2027年归母净利润为4.64/5.43/6.81亿元,EPS为0.75/0.88/1.1元,当前股价对应PE为79.7/68.1/54.4倍,考虑公司自免新产品即将上市,维持“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为中泰证券的曹泽运、穆奕杉。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100033783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688336"],"gpt_icon":0},{"id":"2579435798","title":"三生制药引爆创新药行情,三生国健20CM涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2579435798","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579435798?lang=zh_cn&edition=full","pubTime":"2025-10-31 13:48","pubTimestamp":1761889680,"startTime":"0","endTime":"0","summary":"10月30日,辉瑞在Clinicaltrials.gov网站上注册了PD-1/VEGF双抗PF-08634404(SSGJ-707)的两项全球三期临床试验,分别为与化疗联合治疗晚期非小细胞肺癌(头对头对比Keytruda+化疗)、与化疗 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20251031/c672154564.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"a08235b539b1acf257c7ed4f00bf392e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251031/c672154564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992","BK0239","688336"],"gpt_icon":0},{"id":"2579748128","title":"异动快报:三生国健(688336)10月31日10点32分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2579748128","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579748128?lang=zh_cn&edition=full","pubTime":"2025-10-31 10:35","pubTimestamp":1761878119,"startTime":"0","endTime":"0","summary":"证券之星10月31日盘中消息,10点32分三生国健触及涨停板。目前价格72.96,上涨20.0%。其所属行业生物制品目前上涨。该股为创新药,医药概念热股,当日创新药概念上涨2.14%,医药概念上涨1.94%。10月30日的资金流向数据方面,主力资金净流出250.15万元,占总成交额0.71%,游资资金净流入1246.53万元,占总成交额3.54%,散户资金净流出996.38万元,占总成交额2.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a08235b539b1acf257c7ed4f00bf392e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100017986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2578501806","title":"每周股票复盘:三生国健(688336)Q3净利同比增71.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578501806","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578501806?lang=zh_cn&edition=full","pubTime":"2025-10-26 01:29","pubTimestamp":1761413347,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘,三生国健报收于54.83元,较上周的59.09元下跌7.21%。本周,三生国健10月22日盘中最高价报62.5元。本周关注点来自业绩披露要点:前三季度归母净利润3.99亿元,同比增长71.15%。来自股本股东变化:截至9月30日股东户数降至1.12万户,户均持股增至5.51万股。股本股东变化截至2025年9月30日,三生国健股东户数为1.12万户,较6月30日减少1,640户,降幅12.77%。户均持股数量由4.8万股上升至5.51万股,户均持股市值达312.85万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2578452546","title":"三生国健(688336)2025年三季报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2578452546","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578452546?lang=zh_cn&edition=full","pubTime":"2025-10-25 06:04","pubTimestamp":1761343476,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期三生国健发布2025年三季报。截至本报告期末,公司营业总收入11.16亿元,同比上升18.8%,归母净利润3.99亿元,同比上升71.15%。按单季度数据看,第三季度营业总收入4.74亿元,同比上升38.27%,第三季度归母净利润2.09亿元,同比上升101.41%。本报告期三生国健盈利能力上升,毛利率同比增幅1.95%,净利率同比增幅47.26%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102500005467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336"],"gpt_icon":0},{"id":"2577593513","title":"10月24日三生国健跌8.62%,泰信医疗服务混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2577593513","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577593513?lang=zh_cn&edition=full","pubTime":"2025-10-24 16:11","pubTimestamp":1761293496,"startTime":"0","endTime":"0","summary":"证券之星消息,10月24日三生国健跌8.62%,收盘报54.83元,换手率1.94%,成交量11.94万手,成交额6.63亿元。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为泰信基金的泰信医疗服务混合发起式A。泰信医疗服务混合发起式A目前规模为0.32亿元,最新净值1.1766,较上一交易日下跌2.45%,近一年上涨27.61%。该公募基金现任基金经理为陈颖。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400027609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2577236588","title":"三生国健(688336)披露2025年第三季度报告,10月23日股价上涨0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577236588","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577236588?lang=zh_cn&edition=full","pubTime":"2025-10-23 22:06","pubTimestamp":1761228379,"startTime":"0","endTime":"0","summary":"截至2025年10月23日收盘,三生国健报收于60.0元,较前一交易日上涨0.67%,最新总市值为370.07亿元。近日,三生国健发布了2025年第三季度报告。公告显示,2025年前三季度公司实现营业收入111,599.61万元,同比增长18.80%;归属于上市公司股东的净利润为39,886.02万元,同比增长71.15%。经营活动产生的现金流量净额为281,324.12万元,同比增长1,439.91%。研发投入方面,公司前三季度研发投入合计36,804.38万元,同比增长3.87%。报告期末,公司普通股股东总数为11,202户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300037576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2577377603","title":"三生国健最新公告:第三季度净利润同比增长101.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577377603","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577377603?lang=zh_cn&edition=full","pubTime":"2025-10-23 18:00","pubTimestamp":1761213655,"startTime":"0","endTime":"0","summary":"三生国健(688336.SH)公告称,三生国健(688336.SH)发布2025年第三季度报告,第三季度实现营业收入4.74亿元,同比增长38.27%;归属于上市公司股东的净利润为2.09亿元,同比增长101.41%。前三季度实现营业收入11.16亿元,同比增长18.80%;归属于上市公司股东的净利润为3.99亿元,同比增长71.15%。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300030188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765964064444,"stockEarnings":[{"period":"1week","weight":-0.0429},{"period":"1month","weight":-0.1806},{"period":"3month","weight":0.1108},{"period":"6month","weight":0.0987},{"period":"1year","weight":1.7033},{"period":"ytd","weight":1.774}],"compareEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.0415},{"period":"3month","weight":-0.0133},{"period":"6month","weight":0.1376},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.1411}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"三生国健药业(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11202人(较上一季度减少12.77%)","perCapita":"55060股","listingDate":"2020-07-22","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路399号","registeredCapital":"61678万元","survey":" 三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普、赛普汀、健尼哌。公司是“免疫与炎症全国重点实验室”依托单位、拥有抗体药物国家工程研究中心、国家企业技术中心、上海市抗体技术创新中心、上海抗体工程技术研究中心等国家级和上海市级高新技术平台,承担过国家重大新药创制、“863”计划、国家发改委及上海市重大项目及各部委课题百余项,多次获得上海市级和浦东新区科学技术奖。","listedPrice":28.18},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生国健,688336,三生国健股票,三生国健股票老虎,三生国健股票老虎国际,三生国健行情,三生国健股票行情,三生国健股价,三生国健股市,三生国健股票价格,三生国健股票交易,三生国健股票购买,三生国健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}